About
WHO ARE OLEO?

Oleo is a Medical Cannabis Company

Medical Cannabis

About

Oleo is a medical cannabis company led by forward-thinking entrepreneurs with 25 years medical technology experience. Oleo has developed mobile health (mHealth) solutions to support personalized cannabis treatments in the global medical cannabis industry.

Founded in 2019 with the goal of providing cannabis-based products to Irish patients. Our first cannabis-based product for the treatment of chemotherapy-induced nausea and vomiting were added to Schedule 1 of the Misuse of Drugs Regulations 2021. These flower-based products, along with our Panacea Inhaler device used for vaporisation, are available through Ireland's Medical Cannabis Access Programme (MCAP) and are reimbursable through the drugs payment scheme.

We recognized that many Irish patients and prescribers were unfamiliar with prescription cannabis products, and we wanted to help treatments in any way we could while also minimizing patient risk. As a result, we created and launched the OleoCare platform, which includes a doctor-facing web-based Portal and a patient-facing mobile application.

OleoCare supports and facilitates medical cannabis treatment by tracking dosage and symptoms. Our platform assists clinicians in prioritizing remote care delivery and triaging each patient and case based on near-real-time patient status, allowing for safer, more reliable prescribing while reducing hospital footfall. Our platform also aids clinical research by enabling secure collection of data remotely via mobile apps, streamlining data collection and analysis.

Professor Dymphna Waldron, Prof of Palliative Medicine Saolta Hospitals Group/National University of Galway, Ireland, and Oleo's medical adviser, has over 30 years of palliative care experience and a strong interest in the benefits of cannabinoids. Dymphna has decades of experience conducting research on 'Individual Quality of Life (QoL),' Symptom Bother, Symptom Interference with QoL, and Response Shift in outcome measurement. She has identified clear flaws in research outcome measures to date, and her findings are being incorporated into our app. She is also involved in the use of cannabinoids for nausea, vomiting, and anorexia in cancer patients, and she is about to begin a Phase 2 trial for the same symptom control.

Our small team is working tirelessly to expand access to medical cannabis for patients in Ireland. In January 2023, Oleo added two new products to the MCAP for the treatment of Spasticity associated with multiple sclerosis. Oleo will continue to add products that allow patients greater choice and access as the programme expands.

We would encourage Irish Consultants who are interested in learning more about the Endocannabinoid system to contact us and we’ll arrange training with medical professionals leading the way across Europe.

Interested in learning more? Let’s chat

About
WHO ARE OLEO?

Meet the team

0
    0
    Your Cart
    Your cart is emptyReturn to Shop